The research findings highlight the absence of a connection between clinical benefits and short-term cost savings, with the study authors concluding: "Our 24-month analysis did not demonstrate cost savings, in contrast to industry-sponsored models that project long-term savings (eg, over 10 years) based on trial-derived effectiveness. There have been fewer studies focused on the more recently approved tirzepatide-based drug Zepbound
He commented that while the reduction in headache days is impressive, the study is limited and lacks direct measurements of intracranial pressure
Nutritional supplements and chronic disease: bridging the gap between myth and reality
After receiving DexN, all subjects fell asleep, whereas after receiving DexL, one subject did not fall asleep, resulting in a total of 101/102 (99.0%) of participants falling asleep after Dex
Lysyl oxidase activity is indirectly enhanced through BPC-157's growth factor modulation, producing denser and stronger collagen matrices